What was Pathfinder Cell Therapy’s price range in the past 12 months?
Pathfinder Cell Therapy lowest stock price was $0.00 and its highest was $0.02 in the past 12 months.
What is Pathfinder Cell Therapy’s market cap?
Pathfinder Cell Therapy’s market cap is $667.
When is Pathfinder Cell Therapy’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Pathfinder Cell Therapy overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Pathfinder Cell Therapy pay dividends?
Pathfinder Cell Therapy does not currently pay dividends.
What is Pathfinder Cell Therapy’s EPS estimate?
Pathfinder Cell Therapy’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pathfinder Cell Therapy have?
Pathfinder Cell Therapy has 667,161,000 shares outstanding.
Which hedge fund is a major shareholder of Pathfinder Cell Therapy?
Currently, no hedge funds are holding shares in PFND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pathfinder Cell Therapy
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.